{"url_path":"/sec/esla/8-k/2026-06-30/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1844417/0001213900-26-073847-index.html","accession_number":"0001213900-26-073847","cik":"0001844417","ticker":"ESLA","issuer_name":"Estrella Immunopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1844417/0001213900-26-073847-index.html","primary_entity_key":"0001844417","primary_entity_name":"Estrella Immunopharma, Inc."},"word_count":292,"has_tables":true,"body_markdown":"**Item 5.07. Submission of Matters to a Vote of Security Holders.**\n\n \n\nEstrella Immunopharma, Inc. (the “Company”)\nheld its Combined 2025/2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 29, 2026, at 10:00 a.m. Eastern\nTime by means of remote communication, in a virtual-only format, via live audio webcast.\n\n \n\nAs of the close of business on May 20, 2026, the\nrecord date for the Annual Meeting, there were 43,034,228 shares of the Company’s common stock outstanding and entitled to vote.\nHolders of 30,351,608 shares of common stock were present or represented by proxy at the Annual Meeting, constituting approximately 70.5%\nof the shares of common stock outstanding and entitled to vote and a quorum for the transaction of business.\n\n \n\nOne proposal was submitted to a vote of the Company’s\nstockholders at the Annual Meeting. The proposal is described in detail in the Company’s definitive proxy statement on Schedule\n14A, filed with the Securities and Exchange Commission on May 27, 2026. The final voting results are set forth below.\n\n** **\n\n**Proposal 1— Ratification of Appointment\nof Independent Registered Public Accounting Firm**\n\n** **\n\nThe Company’s stockholders ratified the appointment of Macias Gini\n& O’Connell LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31,\n2026. The final voting results were as follows:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n**Broker Non-Votes**\n\n30,351,203\n \n400\n \n5\n0\n\n \n\nThere were no broker non-votes with respect to Proposal 1. Based on the\nfinal voting results, Proposal 1 was approved.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the\nregistrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**Estrella Immunopharma, Inc.**\n\n \n \n\n \nBy:\n/s/ Peter Xu\n\n \nName: \nPeter Xu\n\n \nTitle:\nChief Financial Officer\n\n \n \n \n\nDate: June 30, 2026"}